Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-drug conjugates - Bayer HealthCare

Next Previous
X
Search
Drug Profile

Research programme: antibody-drug conjugates - Bayer HealthCare

Alternative Names: Anti-C4.4a antibody-drug conjugates; Anti-C4.4a-ADC; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates; Antibody-Eg5 inhibitor conjugates; Antibody-KIF11 inhibitor conjugates; Antibody-kinesin spindle protein inhibitor conjugates; Antibody-KSP inhibitor conjugates; FGFR2-ADC

Latest Information Update: 01 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Seagen
  • Class Antibodies; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; KIF11 protein inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 14 Dec 2023 Seagen has been acquired by Pfizer
  • 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 01 Apr 2017 Pharmacodynamics data from preclinical trials in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top